5 recruiting, 3 active not recruiting, 1 completed, 1 not yet recruiting. 5 Phase 1, 5 Phase 2, 2 Not applicable, 2 Phase 3.
Follow Supportive care measures: new trials by email Literature Review of Supportive care measures trials Research Report on Supportive care measures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comprehensive Management for Terminal Heart Failure Program: Supportive care measures - Heart Failure | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2025-04-01 | 2025-03-27 |
| Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery Postoperative adjuvant lenvatinib, Supportive care measures - Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 276 | 2025-02-01 | 2025-01-08 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 32 | 2024-12-20 | 2026-10-15 |
| Comparative Study Between Using WHO Labour Care Guide & Modified WHO Partograph Supportive care measures, LCG guided labour interference - Labor Onset and Length Abnormalities, 37 or More Completed Weeks of Gestation | Not applicable | Completed | Hend Mahmoud Abdelghany | 230 | 2024-08-01 | 2026-02-23 |
| A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab - Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 38 | 2024-07-17 | 2026-02-18 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-29 |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan - Gastroesophageal Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 473 | 2024-05-03 | 2026-10-22 |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 614 | 2023-12-15 | 2026-10-27 |
| Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures - Non-small Cell Lung Cancer, Solid Tumors | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 30 | 2023-10-26 | 2026-09-02 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Paclitaxel, Irinotecan, Pembrolizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 230 | 2023-05-16 | 2026-10-07 |
Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Heart Failure (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Merck Sharp & Dohme LLC (7) · Hend Mahmoud Abdelghany (1) · National Taiwan University Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (6) · Canada (5) · China (5) · Italy (5) · Japan (5) · South Korea (5) · Spain (5) · Taiwan (5) · United Kingdom (5) · Chile (4) · France (4) · Turkey (Türkiye) (4) · Brazil (3) · Germany (3) · Netherlands (3)
2023 (5)